Posttransplant Recurrence of Primary Glomerulonephritis

Ponticelli, Claudio; Glassock, Richard J.

doi:10.2215/cjn.06720810

Cited by 213 publications

(184 citation statements)

References 127 publications

Supporting

Mentioning

171

Contrasting

Unclassified

Order By: Relevance

“…29 Similar findings were found in other studies, such as that by Lorenz and associates who reported nearly similar results to the latter. 30 The major difference between our study and others may be due to presence of larger number of patients (1321 patients) and also to difference in study methodology, as Lorenz and colleagues used a protocol biopsy in detection of recurrence, whereas in our study only event biopsy was carried out.…”

Section: Discussionsupporting

confidence: 90%

Untitled

Mashaly

Ismail²,

Lotfy³

et al. 2016

Exp Clin Transplant

View full text Add to dashboard Cite

Objectives: Renal allograft function and graft survival depends on many factors, including the source of the graft, immunologic matching between donor and recipient, incidence of acute rejection, and recurrence of the original kidney disease. This work aimed to evaluate the effects of the original kidney disease on patient and graft survival. Materials and Methods: This was a retrospective, single-center study that included 2189 kidney transplant recipients who were transplanted at The Urology and Nephrology Centre, Mansoura University, between 1976 and 2010. Of 2189 recipients, 1350 patients with unknown original kidney disease were excluded, with the remaining 839 patients divided into 4 groups according to their original kidney disease. Results: We found pretransplant dialysis and blood transfusion to be statistically significant among the 4 groups. Regarding induction immunosuppressive therapy, a statistical significance was found between the 4 groups regarding the presence and type of induction therapy, with no statistical significance regarding the type of maintenance immunosuppression. There was no statistical significance between the 4 groups regarding the incidence of acute and chronic rejection. We also found recurrence of original kidney disease to be statistically significant in the 4 groups, particularly in the group that included patients with glomerular disease, where the highest rate of recurrence was reported in patients with focal segmental glomerulosclerosis and membranop roliferative glomerulonephritis, and patient and graft survival was also statistically significant. Conclusions: The original kidney disease has an effect on renal allograft function and graft and patient survival.

show abstract

Section: Discussionsupporting

confidence: 90%

Untitled

Mashaly

Ismail²,

Lotfy³

et al. 2016

Exp Clin Transplant

View full text Add to dashboard Cite

show abstract

“…The use of RTX in primary FSGS in adults has had variable, but mostly negative results in small case series [90], [91] and [92]. However, it may be useful in treating posttransplant relapse [93], [94] and [95]. Interestingly, recent research has shown that RTX may have a direct effect on podocytes, regardless of its action on B-cells, and this could explain the beneficial effect of RTX in these nephrotic disorders that are not clearly associated with auto-antibodies [96].…”

Section: Focal Segmental Glomerulosclerosis and Minimal Change Diseasementioning

confidence: 99%

Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases

Kattah¹,

Fervenza²,

Roccatello³

2013

Autoimmunity Reviews

View full text Add to dashboard Cite

Rituximab is a monoclonal antibody to the CD20 antigen on B-cells that was initially designed and approved for the treatment of non-Hodgkin's B-cell lymphoma in 1997.In the last 15 years, it has emerged as a potent immunosuppressant for many immune-mediated diseases, beginning initially with rheumatoid arthritis, and now extending into several other fields, including clinical nephrology. Based on recent large clinical trials, it is FDA-approved for the treatment of ANCA-associated vasculitis and continues to be studied in off-label usage for many glomerular diseases, including membranous nephropathy, lupus nephritis, and mixed cryoglobulinemia. It has been used as a treatment in nephrotic syndrome in children and adults, including both minimal change disease and focal segmental glomerulosclerosis. Given its efficacy, tolerability and safety profile in comparison to more conventional treatment regimens, RTX is rapidly emerging as a critical treatment modality in glomerular disease.

show abstract

“…Two patterns of clinical presentations are observed: Early recurrence, which is most commonly encountered in pediatric patients and characterized by a massive proteinuria that occurs within hours to days after implantation of the new kidney; late recurrence, which often develops insidiously at several months to years after the transplantation [9] . Many clinical conditions have been recognized as risk factors for recurrence [4,8,10] , including younger age (particularly in children who were > 6-year-old at FSGS onset), mesangial proliferation in the native kidneys, rapid progression of the disease to endstage renal disease (ESRD; < 3 years from onset) for native kidneys, pre-transplant bilateral nephrectomy, non-African race, specific genetic background, heavy proteinuria before transplantation, and, as cited above, loss of previous allografts due to recurrence.…”

Section: Introductionmentioning

confidence: 99%

Update on the treatment of focal segmental glomerulosclerosis in renal transplantation

Messina¹,

Gallo²,

Mella³

et al. 2016

WJT

View full text Add to dashboard Cite

Focal segmental glomerulosclerosis (FSGS) represents one of the most severe glomerular diseases, with frequent progression to end-stage renal disease and a high rate of recurrence in renal allografts (30%-50%). Recurrent FSGS portends a negative outcome, with the hazard ratio of graft failure being two-fold higher then that of other glomerulonephritis. Two patterns of clinical presentations are observed: Early recurrence, which is characterized by massive proteinuria within hours to days after implantation of the renal graft, and late recurrence, which occurs several months or years after the transplantation. Many clinical conditions have been recognized as risk factors for recurrence, including younger age, rapid progression of the disease to end-stage renal disease on native kidneys, and loss of previous renal allografts due to recurrence. However, much less is known about the incidence and risk factors of the so-called "de novo " type of FSGS, for which sufferers are transplanted patients without disease on native kidneys; but, rapid development of allograft failure is frequently observed. Management of both forms is challenging, and none of the approaches proposed to date have been demonstrated as consistently beneficial or effective. In the present review we report an update on the available therapeutic strategies for FSGS in renal transplantation within the context of a critical overview of the current literature.

show abstract

Posttransplant Recurrence of Primary Glomerulonephritis

Cited by 213 publications

References 127 publications

Untitled

Untitled

Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases

Update on the treatment of focal segmental glomerulosclerosis in renal transplantation

Contact Info

Product

Resources

About